Cerus Co. (NASDAQ:CERS) COO Vivek K. Jayaraman Sells 29,985 Shares of Stock

Cerus Co. (NASDAQ:CERS) COO Vivek K. Jayaraman sold 29,985 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $1.45, for a total transaction of $43,478.25. Following the completion of the sale, the chief operating officer now directly owns 1,477,330 shares in the company, valued at approximately $2,142,128.50. This represents a 1.99 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Cerus Stock Performance

Shares of Cerus stock opened at $1.45 on Tuesday. The company has a quick ratio of 1.92, a current ratio of 2.59 and a debt-to-equity ratio of 1.19. Cerus Co. has a 52 week low of $1.38 and a 52 week high of $2.54. The firm’s 50 day moving average is $1.72 and its two-hundred day moving average is $1.75. The firm has a market capitalization of $269.40 million, a P/E ratio of -13.18 and a beta of 1.56.

Cerus (NASDAQ:CERS) last posted its earnings results on Thursday, February 20th. The biotechnology company reported ($0.01) EPS for the quarter, meeting analysts’ consensus estimates of ($0.01). Cerus had a negative net margin of 11.60% and a negative return on equity of 40.55%. The firm had revenue of $50.81 million for the quarter, compared to the consensus estimate of $50.81 million. Research analysts forecast that Cerus Co. will post -0.08 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reissued an “overweight” rating and issued a $4.00 target price on shares of Cerus in a report on Friday, February 21st.

Institutional Trading of Cerus

Several institutional investors and hedge funds have recently made changes to their positions in CERS. Rockport Wealth LLC acquired a new position in Cerus during the fourth quarter worth approximately $25,000. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Cerus in the 4th quarter valued at $25,000. Cibc World Markets Corp acquired a new stake in Cerus during the 4th quarter worth $26,000. R Squared Ltd acquired a new stake in Cerus during the 4th quarter worth $29,000. Finally, Virtu Financial LLC purchased a new position in Cerus during the 4th quarter worth $33,000. 78.37% of the stock is owned by hedge funds and other institutional investors.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.